

#### 4.0.03 DOC Cmte minutes

### Thyroid cancer Committee meeting 4

**Date:** 05/01/21 10:00-16:00

**Location:** Virtual meeting

**Minutes:** Confirmed

**NICE** National Institute for  
Health and Care Excellence

<b>Committee members present:</b>		
Richard Grünewald [RG] – Chair		(Present for notes 1 – 5)
Jeremy Davis [JD] – Topic advisor		(Present for notes 1 – 5)
John Buscombe [JB]		(Present for notes 1 – 5)
Preetha Chengot [PC]		(Present for notes 1 – 5)
Neil Cozens [NC]		(Present for notes 1 – 5)
Fiona Eatock [FE]		(Present for notes 1 – 5)
Kate Farnell [KF]		(Present for notes 1 – 5)
Steve Hyer [SH]		(Present for notes 1 – 3)
Jessica Lishak [JL]		(Present for notes 1 – 5)
Kate Newbold [KN]		(Present for notes 1 – 8)
Sonja Hoy [SH]		(Present for notes 1 – 5)
Iain Nixon [IN]		(Present for notes 1 – 5)
Anh Tran [AT]		(Present for notes 1 – 5)

<b>In attendance:</b>		
Catrina Charlton [CC]	NICE Guideline Commissioning Manager	(Present for notes 1 – 5)
Anne-Louise Clayton [ALC]	NICE Senior Editor	(Present for notes 1 – 5)
Carlos Sharpin [CS]	Guideline Lead	(Present for notes 1 – 5)
Mark Perry [MP]	Senior Research Fellow	(Present for notes 1 – 5)
Shama Mahammed [SM]	Health Economist	(Present for notes 1 – 5)
Alfredo Mariani [AM]	Health Economist	(Present for notes 1 – 5)
Lina Gulhane [LG]	Head of Information Specialists	(Present for note 3)
Giulia Zuodar [GZ]	Project Manager	(Present for notes 1 – 5)
Ahmed Josef [AJ]	Research Fellow (observing)	(Present for notes 1 – 5)

#### 4.0.03 DOC Cmte minutes

##### Apologies:

Vimal Bedia [VB]

Research Fellow

### 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the third meeting on Thyroid cancer. The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included discussing protocols on:

- FNAC or biopsy accuracy
- Management strategy in people with indeterminate FNA
- Molecular testing
- Optimum frequency and length of follow-up for people

### 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was FNAC or biopsy accuracy; Management strategy in people with indeterminate FNA; Molecular testing; Optimum frequency and length of follow-up for people. The following declarations were received:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
IN	GC member	I have been asked to be involved as lead author on another UK set of guidelines for the management of thyroid cancer. These multidisciplinary guidelines are published every few years. I have submitted info on the methodology of the proposed guidelines	Direct, non-financial, professional and personal	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests previously declared did not prevent the attendees from fully participating in the meeting.

### 3. Writing recommendations

#### 4.0.03 DOC Cmte minutes

ALC gave a presentation on writing NICE recommendations.
<b>3. Draft protocols</b>
MP presented draft protocols: <ul style="list-style-type: none"><li>• FNAC or biopsy accuracy</li><li>• Management strategy in people with indeterminate FNA</li><li>• Molecular testing</li><li>• Optimum frequency and length of follow-up for people</li></ul>
<b>4. Health economic methods</b>
AM gave a presentation on health economic methods.
<b>5 Any other business</b>
None.

**Date of next meeting:** 22 February 2021

**Location of next meeting:** Virtual meeting